Hartwig Medical Foundation
To make the right treatment decision, cancer specialists need to collect all the available diagnostic information from the patient and their tumor.
We are contributing to this work by:
Developing
innovative molecular tests, for identifying the characteristics of the tumor.
Collecting and storing
knowledge of and information about the patient and their tumor.
Integrating
the information and knowledge with treatment outcome to accelerate scientific research. This enables us to learn from the data of today’s patients and provide better treatment for the patients of tomorrow.
Share your data
Your contribution to improving the treatment of tomorrow’s patients is important. Share your data, too!
Read moreShare your data and share our vision for the future of cancer diagnosis
Read the latest news
The Role of organoids and Whole Genome Sequencing in precision oncology
Organoids can help determine which patients with metastatic colorectal cancer (mCRC) are likely to respond to chemotherapy and which targeted …
United in Unique – every individual story is unique
On World Cancer Day, attention is drawn worldwide to the impact of this disease This year’s theme, United in Unique, highlights the fact …
Care pathway broad molecular diagnostics approved, important step forward
On World Cancer Day, we reflected on the enormous impact of cancer. But this impact is visible every day—on patients, their …
The role of molecular diagnostics in sarcomas
Between Science and Clinical Practice The use of molecular diagnostics in sarcoma care is receiving growing international attention. Recent studies¹ …
Comprehensive molecular diagnostics closer for more patients thanks to price reduction
Hartwig Medical Foundation reduces the price of its OncoAct Whole Genome Sequencing (WGS) service as of January 1, 2026. This …
New research shows a more significant role of genetic predisposition in adults with glioblastoma
A recent study published in npj Genomic Medicine shows that hereditary predisposition in adult glioblastoma patients is more common than …
Read the latest blogs
How do you analyze 8,000 Tumor/Normal genomes in under two months?
It has been a long time coming: Hartwig Medical Foundation has transitioned to the GRCh38 (hg38) reference genome! For years, …
Read more
Listening, connecting, and building bridges to make more impact for patients with cancer
This is how Robert Jan Lamers describes his role as managing director of Hartwig Medical Foundation. For four months now, …
Read more
Medicines Policy must be based on real world data
The recent decision by the National Health Care Institute to re-evaluate expensive cancer medicines in real-world practice is a logical …
Read more
The complete DNA test is an additional tool to help us discover the origin of the cancer in patients with CUP, often enabling us to identify this primary tumor. In addition, the test often reveals new options for targeted treatment.